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Abstract 35 
Recent definitions of malnutrition include low muscle mass within its diagnostic criteria. In 36 
fact, malnutrition is one of the main risk factors of skeletal muscle loss contributing to the 37 
onset of sarcopenia. However, differences in the screening and diagnosis of skeletal muscle 38 
loss, especially as a result of malnutrition in clinical and community settings, still occur mainly 39 
as techniques and thresholds used vary in clinical practice.  40 
The objectives of this position paper are firstly to emphasize the link between skeletal muscle 41 
loss and malnutrition-related conditions and secondly to raise awareness for the timely 42 
identification of loss of skeletal muscle mass and function in high risk populations. Thirdly to 43 
recognize the need to implement appropriate nutritional strategies for prevention and 44 
treatment of skeletal muscle loss and malnutrition across the healthcare continuum. 45 
Malnutrition needs to be addressed clinically as a muscle-related disorder and clinicians should 46 
integrate nutritional assessment with muscle mass measurements for optimal evaluation of 47 
these two interrelated entities to tailor interventions appropriately. The design of 48 
monitoring/evaluation and discharge plans need to include multimodal interventions with 49 
nutrition and physical exercise that are key to preserve patient’s muscle mass and function in 50 
clinical and community settings. 51 
 52 
Keywords: lean mass loss, skeletal muscle mass, malnutrition, sarcopenia, ageing, continuum 53 
of care 54 
 55 
 56 
 57 
 58 
 59 
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1. Ageing, successful ageing, and nutritional status 61 
The world population is ageing [1] and many people experience frailty, disability and chronic 62 
disease as they get older, which is linked to impaired skeletal muscle and bone health. Ageing 63 
and disease both result in the continuing but progressive decrease in muscle mass, which can 64 
limit the ability to remain independent [2]. Today, healthcare professionals can help patients 65 
prolong the period of good health across the lifespan by advising individuals how to maintain 66 
wellness and good quality of life in addition to providing effective medical management. This 67 
can be achieved by encouraging individuals to maintain physical activity and by providing 68 
dietary advice to ensure their nutritional needs are met [3].  69 
Problems with nutrition are common in older individuals but malnutrition is not an inevitable 70 
part of ageing as the modifiable lifestyle factors of diet and physical activity can be effectively 71 
addressed for prevention and treatment in clinical practice [4]. Therefore, creating the social, 72 
clinical and lifestyle conditions which improve quality of life will help people to stay 73 
independent and active longer.  74 
 75 
2. Muscle as a metabolically active organ 76 
Skeletal muscle is vital to mobility, posture, strength and balance and allows the performance 77 
of exercise and activities of daily living [5, 6]. Moreover, muscle has been identified as a key 78 
metabolic and homeostatic organ via crosstalk between body organs [7]. Muscle plays a 79 
central role in protein metabolism acting as a reservoir of amino acids when the protein needs 80 
of the body are not met by dietary intake, and enables maintenance of the protein content of 81 
other essential tissues and organs [7, 8]. When dietary protein intake is not sufficient, muscle 82 
is broken down leading to loss of lean mass (LM) with potentially serious health consequences. 83 
LM, or lean body mass (LBM), is a fat-free and bone mineral-free component that includes 84 
muscle and other components such as skin, tendons, and connective tissues [9]. 85 
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LM is therefore important during illness, both for its role in balancing the metabolic needs of 86 
other organs and for its reserves of protein for use as energy intermediate substrates. Loss of 87 
LM is also associated with muscle weakness and impaired physical function [10] and 88 
importantly, is exponentially linked to morbidity and mortality (Figure 1).  89 
 90 
 91 
Figure 1. Complications increase with greater lean mass loss. Assuming no preexisting loss. 92 
Adapted from Demling et al 2009 [10]. 93 
 94 
3. Malnutrition contributes to skeletal muscle mass loss 95 
Malnutrition is an increasingly prevalent condition that is the result of lack of intake or uptake 96 
of nutrients (protein, vitamins and minerals) leading to altered body composition (decreased 97 
muscle) and body cell mass [11].  This results in diminished physical and mental function, and 98 
impaired clinical outcomes [11], which can delay recovery from disease and increase mortality 99 
[10]. Malnutrition further contributes to acute or chronic loss of muscle mass and function, in 100 
both the community and hospitalized individuals. Indeed, the latest definition of malnutrition 101 
by The European Society for Clinical Nutrition and Metabolism (ESPEN) has incorporated low 102 
fat free mass (specifically fat free mass index) into the diagnostic criteria [12].  103 
Different psycho-social, physiological, and pathological conditions lead to inadequate dietary 104 
intake, and failure to meet energy and protein requirements in certain populations, especially 105 
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in advancing age or in those with complex disease. In individuals, the causes of insufficient 106 
dietary intake and malnutrition are complex and multi-factorial. Ageing, dementia and 107 
depression, chronic illness, multiple hospitalizations (immobilization) or decreased appetite 108 
occurring alone or in combination all contribute [13, 14].  109 
Consequences of malnutrition are also multi-faceted, leading to loss of muscle mass and 110 
function, which is associated with adverse health outcomes such as mobility-disability, illness 111 
and infections, increased recovery time, poor quality of life and mortality [11, 14] (Figure 2).  112 
This is a vicious cycle where muscle reduced mass and a decline in strength and/or function 113 
represents either a cause or a consequence of metabolic dysfunction and disease development 114 
especially in older adults [15] (Figure 2).  115 
 116 
Figure 2. Relationship between malnutrition, and loss of skeletal muscle mass and function. 117 
 118 
Therefore, early recognition of malnutrition, and timely administration of nutritional care can 119 
also help improve patient’s lives while reducing healthcare costs [13]. 120 
Since malnutrition is so strongly associated with loss of muscle mass and strength, this is 121 
emerging as the new malnutrition challenge in clinical practice. 122 
Malnutrition is one of the main risk factors of sarcopenia, and acts as a driver of loss of muscle 123 
mass and function, which are the main features [16].  Malnutrition and sarcopenia are 124 
common and overlapping in older adults. In fact, both entities are prevalent among older 125 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
6 
 
adults aged 65 years and over, especially in those hospitalized or living in nursing homes [17]. 126 
Therefore, evaluation of muscle mass is crucial for the diagnosis of both conditions.  127 
Another challenge that needs to be taken into account is the presence of malnutrition among 128 
obese persons, especially in light of the growing prevalence of obesity worldwide [18] and the 129 
presence of sarcopenic obesity [19]. Sarcopenic obesity is the presence of a low proportion of 130 
LM despite the presence of obesity [20] and has been independently associated with worse 131 
morbidity and disability than either sarcopenia or obesity alone [21]. This can occur in older 132 
individuals, in those with Type 2 Diabetes Mellitus (T2DM), COPD, and in obese patients with 133 
malignant disorders and post organ transplantations at all ages. Mechanisms include 134 
inflammation and/or inactivity induced muscle catabolism [20, 22].  135 
Representatives of the four largest global Parenteral and Enteral Nutrition (PEN)-societies from 136 
Europe, North and Latin America, and Asia (The European Society for Clinical Nutrition and 137 
Metabolism, ESPEN, American Society for Parenteral and Enteral Nutrition, ASPEN, Federacion 138 
Latinoamericana de Terapia Nutricional, Nutricion Clinica y Metabolismo, FELANPE, and The 139 
Parenteral and Enteral Nutrition Society of Asia, PENSA comprising the Global Leadership 140 
Initiative on Malnutrition, GLIM), have collaborated to create a consensus on the diagnostic 141 
criteria for malnutrition that has been recently published [23]. This consensus group provided 142 
criteria for the diagnosis of malnutrition that can be used for all patients and in all clinical 143 
settings based on a two-step model for risk screening and diagnosis assessment, which 144 
requires at least one etiological criterion (weight loss, low BMI, or reduced muscle mass) and 145 
one phenotypic criterion (reduced food intake or assimilation, or inflammation) [23].  146 
Importantly, low muscle mass has been proposed as part of the definition of malnutrition [23]. 147 
4. Factors affecting rate of skeletal muscle mass and function loss 148 
Muscle accretion and muscle loss have a noticeable life trajectory, i.e. depending on an 149 
individual’s age [24]. Loss of muscle mass and strength is a natural part of ageing [25]. Peak 150 
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muscle mass and strength are achieved around the age of 25 years [26] but after the age of 40-151 
50, loss of skeletal muscle mass accelerates due to decreased physical activity and altered 152 
protein metabolism [25]. More significantly, during the ageing process a greater decrease in 153 
muscle strength and function is observed [25]. Therefore, building muscle before 40 years and 154 
preserving muscle as much as possible during adulthood is a key strategy for healthy ageing.  155 
Illness, injury, bed rest and malnutrition (inactivity) can accelerate the natural, age-related 156 
progression of LM loss [7, 10, 27]. Patients who suffer such episodes may experience 157 
progressive declines in muscle mass, strength and functional capacity. Immobilization and bed 158 
rest, and subsequent skeletal muscle loss, can have negative effects on functional capacity, 159 
such as walking or climbing stairs. Whether bed rest is prolonged or acute, the loss of muscle is 160 
rapid and profound. Most of the skeletal muscle loss occurs during the early part of the bed 161 
rest period [28, 29].  162 
The rate of skeletal muscle loss varies across hospital settings. The severity of the illness or 163 
injury, coupled with increases in inflammation and catabolic hormones, hallmarks of the stress 164 
response, contribute to the progressive and rapid skeletal muscle loss that occurs in patients 165 
who are critically ill [30]. In a study evaluating the rate of skeletal muscle wasting in 63 166 
critically ill patients, it was reported that within 10 days of admission an average 18% 167 
reduction in muscle mass (rectus femoris cross sectional area) was reported [31]. This shows 168 
that skeletal muscle loss occurs early, within days of hospitalization, and rapidly in ICU 169 
patients. In addition, more severe skeletal muscle loss was observed in patients with multi-170 
organ failure as compared with patients with single organ failure. 171 
Altogether, these data show how hospitalization and illness accelerate skeletal muscle loss and 172 
functional decline, and the need for early identification and nutritional intervention.  173 
 174 
5. Clinical conditions associated with skeletal muscle loss 175 
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Beyond ageing, muscle decline is associated with pathological states and chronic diseases, 176 
such as malnutrition, cancer, neurodegenerative disease, chronic kidney disease, chronic 177 
obstructive pulmonary disease (COPD), sepsis, and immune disorders. On top of this, hospital 178 
immobilization and bed rest are devastating to patients who suffer from these conditions [32-179 
34]. Most of these pathological conditions are associated with various degrees of chronic 180 
inflammation, which plays a critical role in the onset of muscle atrophy and malnutrition.   181 
The main factors underlying malnutrition in well-developed regions are disease and its 182 
treatment, which can modify the drive to eat and impact the absorption, metabolism, or 183 
assimilation of nutrients. In such cases, malnutrition is referred to as “disease-related 184 
malnutrition” (DRM) [11]. DRM is characterized by a deficit of energy, protein and other 185 
nutrients, loss of appetite, and disease-related catabolism. DRM is a frequent problem in all 186 
healthcare settings, including hospitals, home care, and sheltered housing [35], and is highly 187 
prevalent in rehabilitation settings [36, 37]. DRM with inflammation is characterized by an 188 
inflammatory response with altered body composition, impaired function and adverse health 189 
outcomes [38, 39]. Finally, DRM with inflammation can be sub-classified into chronic or acute 190 
disease- or injury-related malnutrition. 191 
Cachexia 192 
DRM with inflammation could be considered as synonymous with cachexia [11]. This condition 193 
occurs frequently in patients with cancer, COPD, liver disease, congestive heart failure and 194 
chronic kidney disease. The cachectic phenotype is characterized by both weight loss (caused 195 
by decreased muscle mass and fat mass) and loss of function due to a catabolic inflammatory 196 
response from the underlying disease [40]. In cancer, pre-cachexia, cachexia and refractory 197 
cachexia can be found dependent on the stage of the disease [41]. While most patients with 198 
cachexia are also sarcopenic, not all individuals with sarcopenia have cachexia [24]. The 199 
presence or recurrence of systemic inflammation is key for the diagnosis of cachexia. In 200 
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addition, anorexia, weight loss and reduced fat mass are three elements that can help 201 
differentiate between cachexia and sarcopenia [40].  202 
Acute disease- or injury-related malnutrition 203 
Patients in the Intensive Care Unit (ICU) display significant nutritional challenges and are 204 
nutritionally compromised. Rates of malnutrition on admission to the ICU are reported to be as 205 
high as 60% depending on the patient population and screening tool used [42, 43]. 206 
Malnutrition in ICU patients has been associated with worse outcomes [42, 43] and low muscle 207 
mass specifically has been associated with higher mortality and longer stays length on 208 
ventilation machines [30, 44]. Once in the ICU, these patients experience a rapid and profound 209 
loss of LBM. Rates can be as high as 2% per day, with the highest rates being seen in those with 210 
worse severity of illness [31]. Although the pathophysiology of this muscle wasting is poorly 211 
understood, it is clear that the release of multiple pro-inflammatory cytokines as well as other 212 
catabolic hormones lead to an overall net catabolic balance [31]. In addition, organizational 213 
factors leading to significant underfeeding likely also contribute. The consequences of muscle 214 
wasting in this population are severe, being reported as a contributing factor to post-ICU 215 
functional impairment [45] and self-reported physical function [46]. There are no currently 216 
agreed objective criteria for diagnosis of malnutrition in ICU patients, although early 217 
nutritional intervention is essential in such patients to support lean mass given the above [47, 218 
48]. 219 
DRM without inflammation is also called non-cachectic DRM [11]. This is a form of disease-220 
driven malnutrition in which inflammation is not the major causal mechanism e.g. as a 221 
consequence of dysphagia, neurologic disorders or dementia/cognitive dysfunction. Advanced 222 
ageing contributes to DRM without inflammation due to the presence of anorexia or lack of 223 
appetite, named as “anorexia of ageing”, which is caused by non-inflammatory related 224 
mechanisms Although, the mechanisms are not fully understood, a range of physiological, 225 
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psychological and social factors that may influence appetite and food intake in older adults 226 
have been proposed [49].  227 
 228 
6. Measurement of skeletal muscle loss in malnutrition 229 
Skeletal muscle loss should be appropriately identified in malnourished individuals using 230 
validated tools that allow screening, diagnosis, intervention, and monitoring of overall patient 231 
health even after discharge [24, 50] (Figure 3).  232 
 233 
 234 
Figure 3. Skeletal muscle loss as a consequence of malnutrition is observed across the 235 
continuum of care and should be appropriately addressed in clinical practice. 236 
 237 
Currently, all muscle mass measures are indirect and none are perfect. Indeed, the literature 238 
does not establish consensus on the best technique for measuring muscle mass, but a recent 239 
publication considers dual X-ray absorptiometry (DXA) as a reference standard (but not a gold 240 
standard) [9].  241 
Existing criteria for the identification of malnutrition are mainly based on observations of 242 
recent weight loss and body mass index (BMI), yet, BMI does not always reflect skeletal muscle 243 
loss.  BMI as well as muscle mass varies with ethnicity and race and these differences need to 244 
be considered. In addition, individuals with the same BMI can have different proportions of 245 
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lean and fat mass [51]. Therefore, it is fundamental to stress the importance of measuring 246 
body composition to evaluate muscle mass and strength loss when making assessments of 247 
malnutrition and sarcopenia in clinical practice.   248 
It is important to realize that malnutrition screening and many assessment tools may not take 249 
LM into account, as they were developed before muscle was included in the definition of 250 
malnutrition. BMI has its limitations since it cannot distinguish between fat, muscle, bone 251 
mass, or the distribution of fat across the body. As another limitation of BMI, it might be 252 
important that the change in height associated with aging has implications for interpretation 253 
of the BMI, a commonly used index of nutritional status. So, clinicians need to assess and 254 
measure not only weight, but also muscle mass to tailor interventions appropriately.  255 
Among body composition measurements anthropometry, like calf and arm circumference and 256 
skin-fold thickness [52], as well as bioelectrical impedance analysis (BIA) and ultrasound are 257 
valuable when used taken sequentially over time. According to the EWGSOP consensus 258 
document on the definition and diagnosis of sarcopenia, screening for sarcopenia is 259 
recommended from age 65 years onwards by measuring gait speed, and handgrip strength, 260 
and/or muscle mass [24]. Very recently, a revised European consensus on definition and 261 
diagnosis of sarcopenia has been published to update the original definition (EWGSOP2) [53]. 262 
The EWGSOP2 consensus paper now focuses on low muscle strength as a key feature of 263 
sarcopenia (primary indicator of probable sarcopenia), uses detection of low muscle quantity 264 
and quality to diagnose and identifies physical performance to determine severity. In addition, 265 
simple, specific cut-off points are recommended for measures aimed at facilitating early 266 
detection and treatment in clinical practice [53]. Different techniques currently exist for the 267 
measurement of muscle mass, strength and physical performance, and have been described by 268 
their suitability for use in research and/or clinical practice [24-53] (Table 1). We can expect 269 
new emerging devices and techniques for muscle mass measurements, e.g. ultrasound [53-54].  270 
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 271 
Table 1. Methods routinely available to assess muscle-related outcomes in research and 272 
clinical practice. Adapted from Cruz-Jentoft et al 2010 [24] and 2018 [53]. 273 
These techniques can help determine whether the three diagnostic criteria for sarcopenia are 274 
met. 275 
Another important issue to consider is sarcopenic obesity [11]. Although, there are currently 276 
no commonly accepted criteria for diagnosing sarcopenic obesity beyond those for sarcopenia 277 
and obesity separately, muscle function assessed by strength can serve as a useful indicator of 278 
the condition [11]. 279 
For all these reasons, a sensitive screening approach is needed to capture all individuals 280 
considered to be at risk of malnutrition, followed by a diagnostic assessment using a 281 
combination of physical examination and biochemical analyses [55].   282 
 283 
7. Role of diet and enteral nutrition to prevent lean mass loss across the continuum of care 284 
Across the healthcare continuum, it is important to ensure that patients are able to access and 285 
consume nutritious foods which provide sufficient energy and protein, as well as 286 
micronutrients. Lifestyle interventions factors such as good nutrition and physical exercise are 287 
key to maintaining muscle or slowing muscle decline [29-31]. Growing evidence links nutrition 288 
to muscle health suggesting it is important to maintain an optimal nutritional status to prevent 289 
muscle mass and strength loss in older adults [56]. In fact, optimal nutrition combined with 290 
exercise has been shown to act synergistically against skeletal muscle loss in aging population 291 
[57]. 292 
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Intervening early with nutrition is vital to preserve and re-build muscle that may be lost as a 293 
result of ageing, disease, bed rest, or inadequate food intake. The impact of early nutritional 294 
therapy and physical rehabilitation on LM and self-sufficiency has been assessed in 295 
hospitalized older patients with acute illness [32]. Results showed that early intervention 296 
preserved and built LM and prevented declines in functional performance [32].  297 
Currently, the most researched nutrition intervention to prevent skeletal muscle loss in clinical 298 
populations is protein supplementation. Achieving adequate protein intake through diet alone 299 
can be challenging in the presence of illness and disease, so oral nutritional supplements, 300 
(ONS) or enteral tube feeding can be helpful in preserving and preventing skeletal muscle loss 301 
in both the hospital and community healthcare settings.  302 
The benefits of high quality protein-enriched ONS have been extensively demonstrated [58]. 303 
Research shows that ONS can increase total energy and protein intake without reducing 304 
spontaneous food intake and lead to weight gain and prevention of weight loss in both 305 
hospital and community patients, including older people [14, 58-61]. Furthermore, ONS can be 306 
more effective than food-based snacks of equal energy content to improve micronutrient 307 
intake in older hospitalized patients [62], and provide greater energy and protein intake in 308 
post-operative patients [63].  309 
Branched chain amino acids have been shown to increase skeletal muscle protein synthesis 310 
and net protein balance. In particular, supplementation with leucine, isoleucine, and valine has 311 
been shown to increase skeletal muscle protein synthesis to preserve skeletal muscle loss in 312 
the elderly [64]. Although dietary supplementation with leucine remains controversial, two 313 
recent systematic reviews and meta-analyses concluded that leucine intake significantly 314 
increases the muscle protein fractional synthetic rate and exerts beneficial effects on body 315 
weight and LM in older persons and may be of benefit to address sarcopenia [65, 66]. Results 316 
from a recent study suggest that provision of a supplement containing vitamin D, leucine-317 
enriched whey protein and a mixture of micronutrients may be important to increase gains in 318 
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appendicular LM (aLM) and improved functionality in sarcopenic older adults, as compared to 319 
a control group [67].  320 
More recently, β-hydroxy-β-methyl-butyrate (HMB), an active metabolite of the essential 321 
amino acid leucine, has attracted interest, with reported anabolic and anticatabolic effects on 322 
muscle. Recent research has been focused on the use of HMB to maintain or rebuild muscle 323 
mass in older populations, especially those at risk of LM loss. Some studies have demonstrated 324 
the benefits of HMB supplementation, alone or in combination with other amino acids, for 325 
preserving and rebuilding LM in older adults [27, 68, 69]. A recent study conducted by Kuriyan 326 
et al. [70] revealed an age-related decline in endogenous plasma HMB levels, which was 327 
positively correlated with appendicular aLM and muscle grip strength in young and older 328 
adults. This indicates that HMB supplementation may be beneficial especially for individuals 329 
with or at risk of LM loss, such as older adults or those with disease-related loss of LM. 330 
Moreover, a recent meta-analysis of clinical studies conducted using HMB alone, or combined 331 
with other amino acids, in older populations demonstrated that HMB supplementation was 332 
significantly associated with an increased muscle mass [71]. Even though research on the 333 
effects of HMB in muscle health mainly is limited by the small number of studies, 334 
heterogeneous methodological approaches, and the interaction of HMB with other nutrients 335 
and with exercise, HMB has been documented to prevent muscle mass loss, improve muscle 336 
mass, and increase muscle function and physical performance [72, 73]. Moreover, the 337 
NOURISH study [74], which is one of the largest clinical studies of its kind, showed that 338 
administration of two servings of an ONS containing CaHMB reduced the risk of mortality by 339 
50% through 90 days post-hospital discharge in malnourished, cardiopulmonary patients, 65 340 
years or older, as compared to standard nutritional care and placebo. This clinical trial, 341 
including over 600 patients, also demonstrated improved nutritional status, body weight, and 342 
vitamin D levels over standard care within 90 days of hospital discharge in those individuals 343 
receiving the ONS containing CaHMB.  344 
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Other nutrients that also work as important anabolic stimuli, such as some minerals and 345 
vitamins, also warrant discussion [75]. Regarding the role of minerals, a recent systematic 346 
review [76] evaluated the scientific evidence linking dietary intake of minerals and muscle 347 
mass, muscle strength, and physical performance in older adults. This review highlighted 348 
calcium, potassium, and sodium as important micronutrients for muscle health and nerve 349 
activity, and magnesium, which is known to participate in muscle relaxation and muscle 350 
function [77]. Low levels of some other minerals such as iron, phosphorus and selenium are 351 
related to poor physical performance, muscle weakness, or muscular diseases, respectively 352 
and zinc is able to delay oxidative processes, which are known to contribute to disuse muscle 353 
atrophy. 354 
Dietary intake of vitamin D has also been linked to improved muscle health and decreased risk 355 
of falls and fractures in the elderly. Vitamin D levels are known to decline with age [78, 79]. 356 
Effects of vitamin D supplementation on improving muscle health have been controversial 357 
through diverse findings observed in different deficient populations. A recent systematic-358 
review and meta-analysis including community-dwelling adults concluded that no 359 
improvement in muscle strength after the administration of vitamin D with or without calcium 360 
supplements were observed [80]. However, a large body of evidence suggests that vitamin D 361 
supplementation seems to improve muscle-related parameters particularly in vitamin D-362 
deficient individuals and especially among older adults. In fact, a further systematic review 363 
that included 13 studies in adults aged 60 years and older, found that vitamin D 364 
supplementation at varying doses is associated with beneficial effects on muscle strength and 365 
balance, compared with placebo or standard treatment [81]. These results were consistent 366 
with a newer meta-analysis which included 29 RCTs involving 5,615 individuals across a wide 367 
age range (mean age: 61.1 years) [82].  368 
In addition to providing adequate levels of macro- and micronutrients, follow-up is essential to 369 
ensure continuity of care between healthcare settings. Appropriate monitoring should be 370 
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instigated to confirm that nutritional needs are being met and ensure patients receive 371 
nutritional support for the correct duration of time.  372 
 373 
 8. Conclusions 374 
Skeletal muscle loss is one of the main features of malnutrition in community dwelling and 375 
hospitalized patients and dramatically impacts on their need for care and quality of life. Early 376 
identification of malnutrition in high risk populations is essential, yet current tools to 377 
screen/diagnose malnutrition based on measures of body weight do not reflect skeletal muscle 378 
loss. Malnutrition needs to be addressed as a muscle-related disorder across the continuum of 379 
care in clinical practice (Table 2).  380 
 381 
Table 2. Malnutrition needs to be addressed as a muscle-related disorder across the 382 
continuum of care in clinical practice. Some key messages are provided to tailor appropriate 383 
interventions. 384 
 385 
Early intervention is key to prevent or minimise loss of muscle mass and function. Multimodal 386 
interventions including nutrition and exercise need to be implemented to counteract 387 
malnutrition-related skeletal muscle loss.  High protein, vitamin D and other key nutrients, 388 
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leucine or its active metabolite, HMB, are all valuable approaches to restore muscle anabolism 389 
and combat malnutrition in hospital, and in community health and care settings. Monitoring 390 
and discharge plans are important to ensure continuity of nutritional care between settings, 391 
and to ensure patients receive optimal treatment for the right duration of time to support 392 
muscle mass and functional recovery. Therefore, this position paper highlights the importance 393 
of addressing skeletal muscle loss in malnourished older adults in a timely manner. Some 394 
guidance and recommendations are provided to tailor appropriate intervention, which include 395 
early identification using validated tools and early use of multimodal therapies including 396 
optimal nutrition and exercise to restore muscle anabolism and combat malnutrition in 397 
different care settings.  398 
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Figure 1. Complications increase with greater lean mass loss*. Adapted from Demling
et al 2009 [10].
*Assuming no preexisting loss
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Figure 2. Relationship between malnutrition, and loss of skeletal muscle mass and 
function.
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Figure 3. Skeletal muscle loss as a consequence of malnutrition is observed across the 
continuum of care and should be appropriately addressed in clinical practice.
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Variable Research Clinical practice
Skeletal muscle strength
Grip strength
Chair stand test (chair rise test)
Knee flexion/extension
Peak expiratory flow
Grip strength
Chair stand test (chair rise test)
Skeletal muscle mass
Dual energy X-ray absorptiometry (DXA)
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Bioelectrical impedance analysis (BIA)
Ultrasound
DXA
BIA
Lumbar muscle cross-sectional area by CT
Anthropometry
Physical performance
Short Physical Performance Battery (SPPB)
Gait speed
Timed-up-and-go test (TUG)
400-meter walk or long-distance corridor walk
Stair climb power test
SPPB
Gait speed
TUG
400-m walk
Table 1. Methods routinely available to assess muscle-related outcomes in 
research and clinical practice. Adapted from Cruz-Jentoft et al 2010 [24] and 
2018 [53].
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Malnutrition needs to be addressed as a muscle-related disorder across the 
continuum of care in clinical practice. Some key messages are provided to tailor 
appropriate interventions.
Target Key message
MUSCLE ROLE
Muscle plays a vital structural and metabolic role in maintaining overall individual’s health, 
quality of life and longevity 
SKELETAL MUSCLE 
MAINTANANCE
For optimal maintenance of skeletal muscle with aging, it is important to build muscle 
when young, maintain it in mid-life, and minimize loss in older adulthood
SKELETAL MUSCLE LOSS
Skeletal muscle loss is at the core of malnutrition
MALNUTRITION
Malnutrition acts as a driver of skeletal muscle loss
SKELETAL MUSCLE LOSS 
ASSESSMENT
BMI is an imperfect measure of body composition and clinicians need to measure not only 
weight, but also muscle mass, to tailor interventions appropriately
NUTRITION
Nutrition intervention needs to consider skeletal muscle loss and include those nutrients 
with evidence to have an impact on muscle function
